Hemagen Diagnostics, Inc.
HMGN · OTC
9/30/2012 | 9/30/2011 | 9/30/2010 | 9/30/2009 | |
|---|---|---|---|---|
| Revenue | $4 | $5 | $5 | $5 |
| % Growth | -21.4% | -1.5% | -3.7% | – |
| Cost of Goods Sold | $2 | $3 | $3 | $3 |
| Gross Profit | $2 | $2 | $2 | $2 |
| % Margin | 39.9% | 38.1% | 45.1% | 38.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $2 | $2 | $2 |
| Operating Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -10.8% | -9.2% | 4.5% | -6.4% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$1 | -$1 | -$0 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$1 | -$0 | -$1 |
| % Margin | -22.4% | -17.1% | -3% | -14.9% |
| EPS | -0.059 | -0.06 | -0.01 | -0.05 |
| % Growth | 2.5% | -500% | 80% | – |
| EPS Diluted | -0.059 | -0.06 | -0.01 | -0.05 |
| Weighted Avg Shares Out | 15 | 15 | 15 | 15 |
| Weighted Avg Shares Out Dil | 15 | 15 | 15 | 15 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -6.8% | -5.5% | 8.2% | -3.5% |